Document is current
Any future updates will be listed below
-
Authors
Carrato, A. http://orcid.org/0000-0001-7749-8140
Benavides, M.
Massutí, B.
Ferreiro-Monteagudo, R.
García Alfonso, P.
Falcó, E.
Reboredo, M.
Cano, T.
Gallego, J.
Viéitez, J. M.
Layos, L.
Salud, A.
Polo, E.
Dotor, E.
Durán-Ogalla, G.
Rodriguez-Garrote, M.
Calvo, A.
Grande, E.
Aranda, E.
-
Funding
Funding for this research was provided by:
Bayer Hispania (The Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Madrid, Spain)
- License Information
-
More Information
Article History
Received: 4 December 2018
Accepted: 27 May 2019
First Online: 3 June 2019
Ethics approval and consent to participate
: The study was approved by the Spanish Medicines Agency, by the Regional Clinical Research Ethics Committee of the Community of Madrid (reference number: Acta 5/2013) and was performed in accordance with the Good Clinical Practice guidelines and the last version (Fortaleza 2013) of the Declaration of Helsinki. All patients provided written informed consent before enrolment.
: Not applicable.
: Viéitez has received honoraria for advisory activities from Bayer. Grande has received research fundings from Bayer, Astellas, Pfizer and AstraZeneca. Aranda has received honoraria for advisory role from Amgen, Bayer, Celgene, Merck, Roche and Sanofi. Carrato has received honoraria for advisory activities from Bayer, Pfizer, Merck and Shire. The other authors have stated that they have no conflicts of interest.
